
Zanubrutinib-Gazyva Shows Promise for CLL/SLL, Follicular Lymphoma Lymphoma News Today
Findings of a Phase 1b trial show that zanubrutinib-Gazyva leads to clinically meaningful responses in patients with CLL/SLL and follicular lymphoma.
“lymphoma cancer” – Google News
